Studying the effect of henna on preventing chemotherapy-induced neuropathy

Studying the effectiveness of henna in preventing neuropathy caused by chemotherapy with taxane drugs in cancer patients treated with chemotherapy regimens

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250607066102N1

Enrollment

Registered

2025-07-07

Start date

2025-06-12

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-induced peripheral neuropathy. Paraneoplastic neuromyopathy and neuropathy

Interventions

Intervention 1: Intervention group: Henna purchased from Atabak Company, Yazd, Iran, is made into 50-gram packets and given to patients, which is mixed with lukewarm water and applied to their hands a

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: All patients with cancer who receive taxane chemotherapy drugs. All patients receiving taxanes who are receiving their first course of chemotherapy. Patients should not have previous proven neuropathy. Patients should not have proven diabetes. Patients should not have neurological damage such as Parkinson's, stroke, seizures, etc. They should not have swelling in their hands or feet. Do not have open wounds on your hands or feet.

Exclusion criteria

Exclusion criteria: Having an allergy or allergic reaction to henna Lack of cooperation from patients

Design outcomes

Primary

Measure	Time frame
Chemotherapy-induced peripheral neuropathy score of European organization for research and treatment of cancer Quality of Live questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: EORTC QLQ-CIPN20 questionnaire.;Chemotherapy-induced peripheral neuropathy score from the Neuropathic Pain Symptom Inventory (NPSI) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: NPSI questionnaire.;Chemotherapy-induced peripheral neuropathy score on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: NCI-CTCAE questionnaire.;Nerve conduction velocity (NCV). Timepoint: Before the intervention and 3 weeks after the last intervention. Method of measurement: NCV device.	—

Measure

Time frame

Chemotherapy-induced peripheral neuropathy score of European organization for research and treatment of cancer Quality of Live questionnaire Chemotherapy-Induced Peripheral Neuropathy (EORTC QLQ-CIPN20) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: EORTC QLQ-CIPN20 questionnaire.;Chemotherapy-induced peripheral neuropathy score from the Neuropathic Pain Symptom Inventory (NPSI) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: NPSI questionnaire.;Chemotherapy-induced peripheral neuropathy score on the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) questionnaire. Timepoint: 3 weeks after intervention. Method of measurement: NCI-CTCAE questionnaire.;Nerve conduction velocity (NCV). Timepoint: Before the intervention and 3 weeks after the last intervention. Method of measurement: NCV device.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSahar Rahzani

Arak University of Medical Sciences

saharrahzani79@gmail.com+98 86 3328 7413

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026